Blood DNA test to guide treatment in early lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a “cell-free DNA” blood test to help diagnose and guide treatment decisions for early non-small cell lung cancer. It may help doctors tailor care based on genetic signals seen in the blood before and around surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legally authorized representative) must sign the informed consent form.
- You have non-small cell lung cancer suspected on a chest CT scan or confirmed before surgery.
- After surgery, the lung cancer must be confirmed by pathology (tissue testing).
- Your lung cancer stage must be I through IIIA (early to locally advanced, not spread far).
- You must not have had chemotherapy or radiation for lung cancer before joining the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
This study uses a special blood test to track minimal residual disease (tiny amounts of cancer that may remain) in people with stage IIIB-C non-small cell lung cancer after they receive initial chemotherapy plus immunotherapy. It may help doctors understand whether this blood test can guide further care and improve outcomes.
This study is testing a new blood test that looks for changes in DNA to detect lung cancer early. It's for people with a new lung cancer diagnosis, those with uncertain CT scan results, healthy volunteers, or those with chronic lung problems.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.